What would be a "bad result" on EORTC? I thought the trial was flawed to start and both SUPG and MGI/Eisai know this? Did Eisai pay $4B for a company that had one product that was not going anywhere(EORTC failure) and two drugs that are just promising at this point? If I remember correctly, Eisai forecast $300M in sales for Dacogen in 2010. They must have done alot of DD on Dacogen before the MGI purchase. I have seen companies make bad business moves but I would hope they see something in Dacogen they like.